Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary tr...
Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis
About this item
Full title
Author / Creator
Publisher
Japan: Springer Nature B.V
Journal title
Language
English
Formats
Publication information
Publisher
Japan: Springer Nature B.V
Subjects
More information
Scope and Contents
Contents
Irinotecan hydrochloride, a topoisomerase I inhibitor, has been preliminarily recognized as an effective agent against clear cell carcinoma of the ovary (CCC), but there are few clinical data. Our aim was to compare progression-free survival (PFS) between patients treated with irinotecan hydrochloride and cisplatin (CPT-P) and those with treated wi...
Alternative Titles
Full title
Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_68167156
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_68167156
Other Identifiers
ISSN
1341-9625
E-ISSN
1437-7772
DOI
10.1007/s10147-007-0670-1
